Research group says FDA found no misconduct in Pfizer Lyme vaccine trial it helped run
12 Oct 2023
VaccinePhase 3
Dive Brief:
Clinical trial contractor Care Access on Tuesday said an inspection by the Food and Drug Administration found no evidence of misconduct in a large trial the group helped run of Pfizer and Valneva’s experimental Lyme disease vaccine.
In February, Pfizer and the French vaccine maker said they were removing half of the Phase 3 study’s participants due to concerns about violations committed by a “third-party clinical trial site operator.”
The move pushed the companies’ timeline for when they expect to submit an approval application to 2026 from previous expectations of 2025. According to Pfizer, the vaccine is the only Lyme disease shot in clinical development. The disease, which is transferred by tick bites, can be treated with antibiotics if caught in time but can cause severe health problems.
Dive Insight:
But the setback forced the company to restructure about two months later, leading to layoffs for about half of its staff, according to reporting by Endpoints News.
Care Access on Tuesday said the FDA’s investigation, which lasted from Oct. 2 through Oct. 10, resulted in no violations, so-called Form 483 observations.
“We’re very glad to have had the opportunity finally to undergo this independent, searching review by an FDA expert, which confirmed what we’ve always said about our performance on the VALOR trial and beyond,” said Care Access CEO Ahmad Namvargolian, in a statement.
The Phase 3 study, dubbed VALOR, is still ongoing at other sites not operated by Care Access. Pfizer has begun to enroll new trial participants to replace those that were removed from the study.
So far in clinical testing, the vaccine candidate has produced, among both children and adults, high levels of antibodies against the six strains of Lyme disease.
Another vaccine for Lyme disease, called Lymerix, was previously available, until its developer GSK discontinued it in 2002 due to low demand and concerns of side effects.
'
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.